Literature DB >> 28161578

Consensus M2e peptide conjugated to gold nanoparticles confers protection against H1N1, H3N2 and H5N1 influenza A viruses.

Wenqian Tao1, Brett L Hurst2, Akhilesh Kumar Shakya1, Md Jasim Uddin1, Rohan S J Ingrole1, Mayra Hernandez-Sanabria3, Ravi P Arya3, Lynn Bimler3, Silke Paust3, E Bart Tarbet2, Harvinder Singh Gill4.   

Abstract

The extracellular domain of influenza A ion channel membrane matrix protein 2 (M2e) is considered to be a potential candidate to develop a universal influenza A vaccine. However poor immunogenicity of M2e presents a significant roadblock. We have developed a vaccine formulation comprising of the consensus M2e peptide conjugated to gold nanoparticles (AuNPs) with CpG as a soluble adjuvant (AuNP-M2e + sCpG). We demonstrate that intranasal delivery of AuNP-M2e + sCpG in mice induces lung B cell activation and robust serum anti-M2e immunoglobulin G (IgG) response, with stimulation of both IgG1 and IgG2a subtypes. Using Madin-Darby canine kidney (MDCK) cells infected with A/California/04/2009 (H1N1pdm) pandemic strain, or A/Victoria/3/75 (H3N2), or the highly pathogenic avian influenza virus A/Vietnam/1203/2004 (H5N1) as immunosorbants we further show that the antibodies generated are also capable of binding to the homotetrameric form of M2 expressed on infected cells. Lethal challenge of vaccinated mice with A/California/04/2009 (H1N1pdm) pandemic strain, A/Victoria/3/75 (H3N2), and the highly pathogenic avian influenza virus A/Vietnam/1203/2004 (H5N1) led to 100%, 92%, and 100% protection, respectively. Overall, this study helps to lay the foundation of a potential universal influenza A vaccine.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adjuvants; CpG; Gold nanoparticles; Influenza vaccine; Intranasal vaccination; M2e; Universal influenza vaccine

Mesh:

Substances:

Year:  2017        PMID: 28161578      PMCID: PMC5572660          DOI: 10.1016/j.antiviral.2017.01.021

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  46 in total

1.  Endogenous IL-17 as a mediator of neutrophil recruitment caused by endotoxin exposure in mouse airways.

Authors:  Masahide Miyamoto; Olof Prause; Margareta Sjöstrand; Martti Laan; Jan Lötvall; Anders Lindén
Journal:  J Immunol       Date:  2003-05-01       Impact factor: 5.422

2.  α-Galactosylceramide potently augments M2e-induced protective immunity against highly pathogenic H5N1 avian influenza virus infection in mice.

Authors:  Kai Li; Jing Luo; Chengmin Wang; Hongxuan He
Journal:  Vaccine       Date:  2011-08-10       Impact factor: 3.641

3.  Assembly and characterization of biomolecule-gold nanoparticle conjugates and their use in intracellular imaging.

Authors:  Alexander Tkachenko; Huan Xie; Stefan Franzen; Daniel L Feldheim
Journal:  Methods Mol Biol       Date:  2005

4.  Development of effective vaccines against pandemic influenza.

Authors:  Kanta Subbarao; Brian R Murphy; Anthony S Fauci
Journal:  Immunity       Date:  2006-01       Impact factor: 31.745

Review 5.  Virus-induced humoral immunity: on how B cell responses are initiated.

Authors:  Franziska Zabel; Thomas M Kündig; Martin F Bachmann
Journal:  Curr Opin Virol       Date:  2013-06-01       Impact factor: 7.090

6.  Immunostimulatory CpG-oligonucleotides induce functional high affinity IL-2 receptors on B-CLL cells: costimulation with IL-2 results in a highly immunogenic phenotype.

Authors:  T Decker; F Schneller; M Kronschnabl; T Dechow; G B Lipford; H Wagner; C Peschel
Journal:  Exp Hematol       Date:  2000-05       Impact factor: 3.084

7.  Immunization with biodegradable nanoparticles efficiently induces cellular immunity and protects against influenza virus infection.

Authors:  Torben Knuschke; Viktoriya Sokolova; Olga Rotan; Munisch Wadwa; Matthias Tenbusch; Wiebke Hansen; Peter Staeheli; Matthias Epple; Jan Buer; Astrid M Westendorf
Journal:  J Immunol       Date:  2013-05-10       Impact factor: 5.422

Review 8.  Avian influenza virus (H5N1): a threat to human health.

Authors:  J S Malik Peiris; Menno D de Jong; Yi Guan
Journal:  Clin Microbiol Rev       Date:  2007-04       Impact factor: 26.132

9.  Enhancement of mucosal immune response against the M2eHBc+ antigen in mice with the fusion expression products of LTB and M2eHBc+ through mucosal immunization route.

Authors:  Guo-guang Zhang; Dong-xiao Li; Hui-huang Zhang; Ya-ming Zeng; Liang Chen
Journal:  Vet Res Commun       Date:  2009-05-22       Impact factor: 2.459

10.  Mucosal vaccination with recombinant Lactobacillus casei-displayed CTA1-conjugated consensus matrix protein-2 (sM2) induces broad protection against divergent influenza subtypes in BALB/c mice.

Authors:  Mohammed Y E Chowdhury; Rui Li; Jae-Hoon Kim; Min-Eun Park; Tae-Hwan Kim; Prabuddha Pathinayake; Prasanna Weeratunga; Man Ki Song; Hwa-Young Son; Seung-Pyo Hong; Moon-Hee Sung; Jong-Soo Lee; Chul-Joong Kim
Journal:  PLoS One       Date:  2014-04-08       Impact factor: 3.240

View more
  36 in total

1.  Investigation of tunable acetalated dextran microparticle platform to optimize M2e-based influenza vaccine efficacy.

Authors:  Naihan Chen; Matthew D Gallovic; Pamela Tiet; Jenny P-Y Ting; Kristy M Ainslie; Eric M Bachelder
Journal:  J Control Release       Date:  2018-09-24       Impact factor: 9.776

2.  Current Prospects in Peptide-Based Subunit Nanovaccines.

Authors:  Prashamsa Koirala; Sahra Bashiri; Istvan Toth; Mariusz Skwarczynski
Journal:  Methods Mol Biol       Date:  2022

3.  Tyrosine-Based Cross-Linking of Peptide Antigens to Generate Nanoclusters with Enhanced Immunogenicity: Demonstration Using the Conserved M2e Peptide of Influenza A.

Authors:  Logan R Wilks; Gaurav Joshi; Megan R Grisham; Harvinder Singh Gill
Journal:  ACS Infect Dis       Date:  2021-08-25       Impact factor: 5.578

4.  Designing inorganic nanomaterials for vaccines and immunotherapies.

Authors:  Krystina L Hess; Igor L Medintz; Christopher M Jewell
Journal:  Nano Today       Date:  2019-05-29       Impact factor: 20.722

5.  Matrix Protein 2 Extracellular Domain-Specific Monoclonal Antibodies Are an Effective and Potentially Universal Treatment for Influenza A.

Authors:  Lynn Bimler; Sydney L Ronzulli; Amber Y Song; Scott K Johnson; Cheryl A Jones; Teha Kim; Duy T Le; S Mark Tompkins; Silke Paust
Journal:  J Virol       Date:  2020-12-02       Impact factor: 6.549

6.  Inhibitory activity of selenium nanoparticles functionalized with oseltamivir on H1N1 influenza virus.

Authors:  Yinghua Li; Zhengfang Lin; Min Guo; Yu Xia; Mingqi Zhao; Changbing Wang; Tiantian Xu; Tianfeng Chen; Bing Zhu
Journal:  Int J Nanomedicine       Date:  2017-08-09

7.  Inhibition of H1N1 influenza virus-induced apoptosis by functionalized selenium nanoparticles with amantadine through ROS-mediated AKT signaling pathways.

Authors:  Yinghua Li; Zhengfang Lin; Min Guo; Mingqi Zhao; Yu Xia; Changbing Wang; Tiantian Xu; Bing Zhu
Journal:  Int J Nanomedicine       Date:  2018-04-03

Review 8.  Universal Vaccines and Vaccine Platforms to Protect against Influenza Viruses in Humans and Agriculture.

Authors:  Daniela S Rajão; Daniel R Pérez
Journal:  Front Microbiol       Date:  2018-02-06       Impact factor: 5.640

Review 9.  Emerging Advances of Nanotechnology in Drug and Vaccine Delivery against Viral Associated Respiratory Infectious Diseases (VARID).

Authors:  Amir Seyfoori; Mahdieh Shokrollahi Barough; Pooneh Mokarram; Mazaher Ahmadi; Parvaneh Mehrbod; Alireza Sheidary; Tayyebeh Madrakian; Mohammad Kiumarsi; Tavia Walsh; Kielan D McAlinden; Chandra C Ghosh; Pawan Sharma; Amir A Zeki; Saeid Ghavami; Mohsen Akbari
Journal:  Int J Mol Sci       Date:  2021-06-28       Impact factor: 5.923

10.  M2e conjugated gold nanoparticle influenza vaccine displays thermal stability at elevated temperatures and confers protection to ferrets.

Authors:  Rohan S J Ingrole; Wenqian Tao; Gaurav Joshi; Harvinder Singh Gill
Journal:  Vaccine       Date:  2021-07-21       Impact factor: 4.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.